Method for augmenting the inotropic effects of .beta.-adrenergic agonists using pyruvate therapy
US6153647A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 12, 1998 |
| Grant date | Nov 28, 2000 |
| Priority date | — |
| Expiry date | Nov 12, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for treating medical patients suffering from cardiac trauma by co-administering pyruvate with a .beta.-adrenergic agonist. This method for treating cardiac trauma, such as ischemic reperfusion injury and heart failure, augments the inotropic effects of .beta.-adrenergic agents. Typical .beta.-adrenergic agonists are epinephrine, norepinephrine, dobutamine, and isoproterenol. The amount of .beta.-adrenergic agonist necessary to achieve a 50 percent increase of cardiac power is diminished five-fold when co-administered with pyruvate. Since high concentrations of agonists have many detrimental and hazardous side effects in patients, this invention would have important applications in the treatment of patients with cardiac trauma such as ischemia reperfusion injury.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.